Newly diagnosed epilepsy and pharmacogenomics research: A step in the right direction?

Epilepsy and Behavior

Volumn 22, Issue 1, 2011, Pages 3-8

  Johnson, Michael R ^a   Tan, Nigel C K ^b   Kwan, Patrick ^c   Brodie, Martin J ^d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d WESTERN INFIRMARY   (United Kingdom)

Author keywords

Efficacy; Genes; Newly diagnosed epilepsy; Pharmacogenomics; Side effects; Studies

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; HLA B ANTIGEN;

ANTICONVULSANT THERAPY; CONCEPTUAL FRAMEWORK; DATA BASE; DRUG EFFICACY; DRUG MARKETING; EFFECT SIZE; EPILEPSY; ETHNICITY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE REPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HERITABILITY; HUMAN; MEDICAL ETHICS; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE TRAIT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BIOMEDICAL RESEARCH; DATABASES, FACTUAL; EPILEPSY; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS;

EID: 80052484565     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.02.012     Document Type: Review

References (61)

1. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
2. Mohanraj R., Brodie M.J. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006, 13:277-282.
3. Sillanpäa M., Schmidt D. Natural history of treated childhood-onset epilepsy: prospective long-term population-based study. Brain 2006, 129:617-624.
4. Choi H., Heiman G., Pabdis D., et al. Seizure remission and relapse in adults with intractable epilepsy: a cohort study. Epilepsia 2008, 49:1440-1445.
5. Schiller Y., Najjar Y. Quantifying response to antiepileptic drugs: effect of past treatment history. Neurology 2008, 70:54-65.
6. Schiller Y. Seizure relapse and development of drug resistance following long-term remission. Arch Neurol 2009, 66:1233-1239.
7. Berg A.T., Levy S.R., Testa F.M., D'Souza R. Remission of epilepsy after two drug failures in children: a prospective study. Ann Neurol 2009, 65:510-519.
8. Sillanpäa M., Schmidt D. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain 2009, 132:989-998.
9. Geerts A., Arts W.F., Stroink H., et al. Cause and outcome of childhood epilepsy: a 15 year follow-up of the Dutch Study of Epilepsy in Childhood. Epilepsia 2010, 1189-1197.
10. Brodie M.J., Bamagous G., Kwan P. Improved outcomes in newly diagnosed epilepsy. Epilepsia 2009, 50(Suppl. 11):411-412.
11. Kwan P., Arzimanoglou A., Berg A.T., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
12. Cockerell O.C., Johnson A.L., Sander J.W.A.S., et al. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet 1995, 346:140-144.
13. MacDonald B.E., Johnson A.L., Goodridge G.M. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000, 48:833-841.
14. Dlugos D.J., Sammel M.D., Strom B.L., Farrar J.T. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 2001, 57:2259-2264.
15. Hitiris N., Mohanraj R., Norrie J., et al. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007, 75:192-196.
16. Camfield C., Camfield P., Gordon K., et al. Does the number of seizures before treatment influence ease of control or remission of childhood epilepsy? Not if the number is 10 or less. Neurology 1996, 46:41-44.
17. Leschziner G., Jorgensen A.L., Andrew T., et al. Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol 2006, 5:668-676.
18. Semah F., Picot M.C., Adam C., et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence?. Neurology 1998, 51:1256-1262.
19. Stephen L.J., Kwan P., Brodie M.J. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment?. Epilepsia 2001, 42:357-362.
20. Mohanraj R., Brodie M.J. Outcomes in newly diagnosed localisation-related epilepsies. Seizure 2005, 14:318-323.
21. Sillanpäa M., Schmidt D. Seizure clustering during drug treatment affects seizure outcome and mortality of childhood-onset epilepsy. Brain 2008, 131:938-944.
22. Kanner A.M., Byrne R., Chicharro A., et al. A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology 2009, 72:793-799.
23. Jobe P.C., Daily J.W., Wernicke J.F. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 1999, 13:317-356.
24. Mohanraj R., Brodie M.J. Outcomes of newly diagnosed idiopathic generalised epilepsy syndromes in a non-paediatric setting. Acta Neurol Scand 2007, 115:204-208.
25. Brodie M.J. Response to antiepileptic drug therapy: winners and losers. Epilepsia 2006, 46(Suppl. 10):31-32.
26. Franciotta D., Kwan P., Perruca E. Genetics basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 2009, 22:144-149.
27. Daly A.K. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010, 11:241-246.
28. U.S. Food and Drug Administration Table of pharmacogenomic biomakers in drug labels Available at:, Accessed: 11 January 2011. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
29. Price water house Coopers' Health Research Institute The new science of personalized medicine Available at:. http://www.pwc.com/personalizedmedicine.
30. Baulac M., Pitkanen Research priorities in epilepsy for the next decade: a representative view of the European scientific community. Epilepsia 2009, 50:571-583.
31. Moons K.G.M., Royston P., Vergouwe Y., et al. Prognosis and prognostic research: what, why, and how?. Br Med J 2009, 338:1317-1320.
32. Beume L.A., Steinhoff B.J. Long-term outcome of difficult-to-treat epilepsy in childhood. Neuropediatrics 2010, 41:135-139.
33. Chadwick D. Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study. Brain 1999, 122:441-448.
34. Marson A., Jacoby A., Johnson A., et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomized controlled trial. Lancet 2005, 365:2007-2013.
35. Petrovski S., Szoeke C.E., Sheffield L.J., et al. Multi-SNP pharmacogenomic classifier is superior to single-SNP models for predicting drug outcome in complex diseases. Pharmacogenet Genomics 2009, 19:147-152.
36. Yang J., Wray N.R., Visscher P.M. Comparing apples and oranges: equating power of case-control and quantitative trait association studies. Genet Epidemiol 2010, 34:254-257.
37. Johnson M.R., Milne R.L., Torn-Broers Y., Hopper J.L., Scheffer I.E., Berkovic S.F. A twin study of genetic influences on epilepsy outcome. Twin Res 2003, 6:140-146.
38. Senn S. Individual response to treatment: is it a valid assumption. Br Med J 2004, 329:966-968.
39. Kim L.G., Johnson T.L., Marson A.G., Chadwick D.W. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 2006, 5:317-322.
40. Rogawski M.A., Johnson M.R. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 2008, 8:127-130.
41. Johnson M.R. The genetic contribution to epilepsy: the known and missing heritability. The causes of epilepsy 2011, 63-67. Cambridge Univ. Press, Cambridge. S.D. Shorvon, F. Andermann, R. Guerrini (Eds.).
42. Goldstein D.B. Common genetic variation and human traits. N Engl J Med 2009, 360:1696-1698.
43. Eleftherohorinou H., Wright V., Hoggart C., et al. Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases. PLoS ONE 2009, 4:e8068.
44. Schadt E.E. Molecular networks as sensors and drivers of common human diseases. Nature 2009, 461:218-223.
45. Hunter D.J. Gene-environment interactions in human diseases. Nat Rev Genet 2005, 6:287-298.
46. Dempfle A., Scherag A., Hein R., Beckmann L., Chang-Claude J., Schäfer H. Gene-environment interactions for complex traits: definitions, methodological requirements and challenges. Eur J Hum Genet 2008, 16:1164-1172.
47. Kasperavici'te D., Sisodiya S.M. Epilepsy pharmacogenetics. Pharmacogenomics 2009, 10:817-836.
48. Tan N.C., Berkovic S.F. The Epilepsy Genetic Association Database (epiGAD): analysis of 165 genetic association studies, 1996-2008. Epilepsia 2010, 51:686-689.
49. Szoeke C., Sills G.J., Kwan P., et al. Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts. Epilepsia 2009, 50:1689-1696.
50. Chung W.H., Hung S.I., Hong H.S., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 1:428-486.
51. Man C.B., Kwan P., Baum L., Yu E., Lau K.M., Cheng A.S., Ng M.H. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007, 48:1015-1018.
52. Motsinger-Reif A.A., Jorgenson E., Relling M.V., et al. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics July 15 2010, PMID:20639796, [Electronic publication ahead of print].
53. Simón-Sánchez J., Singleton A. Genome-wide association studies in neurological disorders. Lancet Neurol 2008, 7:1067-1072.
54. Mullen S.A., Crompton D.E., Carney P.W., Helbig I., Berkovic S.F. A neurologist's guide to genome-wide association studies. Neurology 2009, 10:558-565.
55. Crowley J.J., Sullivan P.F., McLeod H.L. Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 2009, 10:161-163.
56. Bournissen F.G., Moretti M.E., Juurlink D.N., Koren G., Walker M., Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 2009, 50:898-903.
57. Kasperavici'te D., Catarino C.B., Heinzen E.L., et al. Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study. Brain 2010, 133:2136-2147.
58. Zeggini E., Ioannidis J.P. Meta-analysis in genome-wide association studies. Pharmacogenomics 2009, 10:191-201.
59. Lipton P. Pharmacogenetics: the ethical issues. Pharmacogenomics J 2003, 3:14-16.
60. Löscher W., Klotz U., Zimprich F., Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009, 50:1-23.
61. Janssens A.C.J.W., van Duijn C.M. Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 2008, 17:R166-R173.